Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy

• Published in: Life sciences (1973) Vol. 102; no. 2; pp. 98 - 104
• Main Authors: Sakai, Satoshi, Shimojo, Nobutake, Kimura, Taizo, Tajiri, Kazuko, Maruyama, Hidekazu, Homma, Satoshi, Kuga, Keisuke, Mizutani, Taro, Aonuma, Kazutaka, Miyauchi, Takashi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 02.05.2014
• Subjects: Animals; Animals, Newborn; c-Jun; Cardiomegaly - chemically induced; Cardiomegaly - metabolism; Cardiomegaly - prevention & control; Cardiomyocyte hypertrophy; Cells, Cultured; Endothelin-1; Endothelin-1 - antagonists & inhibitors; Endothelin-1 - toxicity; Fatty Acids, Monounsaturated - pharmacology; Fatty Acids, Monounsaturated - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Indoles - pharmacology; Indoles - therapeutic use; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - metabolism; Myocytes, Cardiac - pathology; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase - antagonists & inhibitors; Peptidylprolyl Isomerase - biosynthesis; Peptidylprolyl Isomerase - physiology; Pin1; Rats; Rats, Sprague-Dawley; Statin; Treatment Outcome; c-Jun; Pin1; Cardiomyocyte hypertrophy; Statin; Endothelin-1
• ISSN: 0024-3205; 1879-0631
• DOI: 10.1016/j.lfs.2014.03.018

Cardiac hypertrophy is elicited by endothelin (ET)-1 as well as other neurohumoral factors, hemodynamic overload, and oxidative stress; HMG-CoA reductase inhibitors (statins) were shown to inhibit cardiac hypertrophy partly via the anti-oxidative stress. One of their common intracellular pathways is the phosphorylation cascade of MEK signaling. Pin1 specifically isomerizes the phosphorylated protein with Ser/Thr-Pro bonds and regulates their activity through conformational changes. There is no report whether the Pin1 activation contributes to ET-1-induced cardiomyocyte hypertrophy and whether the Pin1 inactivation contributes to the inhibitory effect of statins. The aim of this study was to reveal these questions. We assessed neonatal rat cardiomyocyte hypertrophy using ET-1 and fluvastatin by the cell surface area, ANP mRNA expression, JNK and c-Jun phosphorylation, and [3H]-leucine incorporation. Fluvastatin inhibited ET-1-induced increase in the cell surface area, ANP expression, and [3H]-leucine incorporation; and it suppressed the signaling cascade from JNK to c-Jun. The phosphorylated Pin1 level, an inactive form, was decreased by ET-1; however, it reached basal level by fluvastatin. Furthermore, Pin1 overexpression clearly elicited cardiomyocyte hypertrophy, which was inhibited by fluvastatin. This is the first report that ET-1-induced cardiomyocyte hypertrophy is mediated through the Pin1 activation and that the inhibitory effect of fluvastatin on cardiomyocyte hypertrophy would partly be attributed to the suppression of the Pin1 function. This study firstly suggests that Pin1 determines the size of hypertrophied cardiomyocyte by regulating the activity of phosphorylated molecules and that statins exert their pleiotropic effects partly via Pin1 inactivation.